Therapy engineering platform: PleoBot™ & PAC (Patient Avatar Cohort)
Tangramed combines AI-assisted network pharmacology and patient-derived robustness testing to support target, indication, combination and Multimodal Therapy decisions.
One platform, multiple strategic decisions.
Tangramed’s platform combines two complementary capabilities.
1. PleoBot™
AI-assisted network pharmacology for target, indication, combination and MMT concept prioritization.
2. Patient Avatar Cohort
Patient-derived robustness testing across relevant biological diversity.
How Integral Therapy Design uses the platform
Integral Therapy Design is Tangramed’s development framework, using PleoBot™ and PAC to design, optimize and benchmark Multimodal Therapy programs.
PleoBot™
+
PAC
ITD
1. PleoBot™ Deep Dive.
Engineered to prioritize therapeutic hypotheses at the network level, our proprietary PleoBot™ platform integrates multi-omics data with clinical context to identify and rank high-potential targets, combinations and indications.
01. Integrate
Integrate multi-omics evidence, disease networks, and clinical-development context into a unified biological framework.
02. Model
Construct a network graph that visualizes complex interactions and biological pathways across diverse disease states.
03. Prioritize
Rank targets, indications, and combinations using expert scientific curation and predictive biological rationale.
04. Interpret
Scientist-led interpretation of AI outputs, ensuring biological plausibility and clinical relevance for development teams.
05. Deliver
Provide decision-ready outputs, including biological rationale and recommended validation strategies for Go/No-Go gates.
Expert Curation.
PleoBot™ supports scientific and development decision-making; it does not replace expert judgment. Tangramed scientists curate and interpret outputs, especially in complex or data-sparse diseases.
Multi-Omics Integration
We integrate multi-omics evidence, disease networks, and clinical-development context to identify the most biologically plausible targets.
Biological Rationale
AI-assisted outputs are interpreted by Tangramed scientists to ensure every hypothesis is grounded in biological reality and translational feasibility.
Development recommendations
We provide a recommended validation strategy, identifying limitations and next-step logic to support robust clinical development decisions.
2. Patient Avatar Cohort (PAC) Framework.
PAC is Tangramed’s patient-derived testing capability for assessing the robustness of Multimodal Therapy concepts across biological diversity.
We use patient-specific iPSC models and disease-relevant human models to benchmark therapeutic concepts against biological diversity, supporting translational decision-making.
01
Seed Cohort
Integrating genetic and biological diversity into the testing framework.
02
iPSC Models
Utilizing patient-specific induced pluripotent stem cells to model disease.
03
Robustness Matrix
Mapping biological responses across diverse patient populations and models.
04
Decision Gate
Providing quantitative evidence for Go, Optimize, or No-Go decisions.
PAC Robustness Testing
How partners benefit from the therapy engineering platform.
PleoBot™ powers focused partner-facing R&D services and discovery collaborations. PAC is available selectively through Tangramed’s proprietary pipeline and partner-funded development programs where substantial shared value creation is possible.
R&D Services
PleoBot™-powered R&D services. We provide ranked matrices, biological rationale, and development recommendations to support target, indication, and combination prioritization.
Pipeline
Available selectively through Tangramed’s proprietary pipeline. Selected concepts may progress into Integral Therapy Design, including Patient Avatar Cohort robustness testing for complex diseases.
Scientific Diligence
Independent scientific and translational assessment for investment teams. We pressure-test therapeutic assets, targets, and platforms to ensure scientific and translational credibility.